8 January 2014 – Baxter International Inc. has sold its legacy Continuous Renal Replacement Therapy (CRRT) business to Nikkiso America, Inc. CRRT is a therapy used primarily for patients in the ICU in need of blood purification due to acute kidney injury or fluid overload. Under the terms of the transaction, Nikkiso acquired Baxter’s legacy CRRT portfolio, including its acute renal therapy product line: the Aquarius™ System, Aqualine™ and Aquaset™ tubing sets, Aquamax™ hemofilters and Accusol solution. The acquisition also included, among others, the transfer of marketing and distribution rights, intellectual property, and associated agreements.

Walder Wyss AG has advised Baxter AG and Baxter Healthcare SA as Swiss legal advisor. The team was led by Urs P. Gnos (Partner, Corporate/M&A) and further included Thomas Meister (Partner, Tax), Simon Kehl (Associate, Corporate/M&A), Janine Corti (Associate, Tax), Andrea S. Hauser (Associate, IP/IT-Health Care), Samuel Lieberherr (Associate, Corporate/M&A), and Manuel B. Mühlestein (Junior Associate, Corporate/M&A).